Genmab AS Stock Target Price and Analyst Consensus
| GMAB Stock | USD 20.65 0.18 0.88% |
The current analyst and expert consensus on Genmab AS is Buy with 5 hold recommendations. The current projected Genmab AS target price consensus is 44.78 with 9 analyst opinions. One of the most common ways Genmab AS analysts use to provide buy-or-sell recommendation to the public are conference calls analysis and financial statements evaluations. Some experts can also talk to Genmab AS vendors, executives, and/or customers. Note, the total number of analysts currently providing their opinion is not significant to determine adequate consensus on Genmab AS. We strongly encourage you to use your own analysis of Genmab AS to validate this buy or sell advice. Genmab AS recommendation module provides expert sentiment on the projected Genmab AS target price to derive its highest and lowest estimates based on target price standard deviation of 1.46.
Lowest Forecast 40.75 | Highest Forecast 49.71 | Target Price 44.78 |
Genmab |
It's important to approach Genmab AS's target price projections with caution. While they can be useful as part of a broader investment strategy, they are inherently speculative and subject to various kinds of risk, including market volatility and unforeseen external factors. Always consider multiple aspects and do your own research when making investment decisions.
Analysts determine stock price targets through various methods, including financial modeling, peer comparison, and company analysis. The stock price target is the analyst's best estimate of the future price of a stock and is used by investors to make investment decisions. However, it is important to note that stock price targets are not guaranteed, and the actual price of a stock can differ significantly from the target due to various factors such as market conditions, economic events, and company developments.
Steps to utilize Genmab AS price targets
Genmab AS's stock target price is an estimate of its future price, usually made by analysts. Using Genmab AS's target price to determine if it is a suitable investment can be done through the following steps:- Look at Genmab AS's target prices provided by various analysts and compare them. This can help you gain a more balanced view of the Stock's potential.
- Look at the analyst's track record to determine if they have a history of accurately predicting stock prices.
- Look at the Company's financials, including revenue, earnings, and debt, to determine if it is in good financial health.
- Consider market conditions. For example, take into account the state of the economy, competition, and regulatory environment, to determine if Genmab AS's stock is likely to perform well.
- Diversify your portfolio and do not rely solely on stock target prices to make investment decisions. Invest in a mix of stocks, bonds, and other assets to manage risk.
Additional Genmab AS Value Projection Modules
Most investment researchers agree that the mispricing and readjustment of any Stock value happens often and is sometimes even predictable, but there is no strong theory explaining why it happens. The current price of Genmab AS is a key component of Genmab AS valuation and have some predictive power on the future returns of a Genmab AS.Trending Themes
If you are a self-driven investor, you will appreciate our idea-generating investing themes. Our themes help you align your investments inspirations with your core values and are essential building blocks of your portfolios. A typical investing theme is an unweighted collection of up to 20 funds, stocks, ETFs, or cryptocurrencies that are programmatically selected from a pull of equities with common characteristics such as industry and growth potential, volatility, or market segment. | Casinos Invested over 90 shares | |
 | Macroaxis Index Invested few shares | |
 | FinTech Invested over 60 shares | |
 | Hedge Favorites Invested over 100 shares | |
 | Banking Invested over 20 shares | |
 | Macroaxis Picks Invested over 40 shares | |
 | Blockchain Invested few shares | |
 | Momentum Invested few shares | |
 | Dividend Beast Invested over 50 shares | |
 | Warren Buffett Holdings Invested few shares | |
 | Manufacturing Invested over 30 shares | |
Check out Macroaxis Advice on Genmab AS to cross-verify analyst projections. Unlike analyst recommendations, Macroaxis provides advice only from the perspective of investor risk tolerance and investment horizon. For information on how to trade Genmab Stock refer to our How to Trade Genmab Stock guide.You can also try the Money Managers module to screen money managers from public funds and ETFs managed around the world.
Please note, the presentation of Genmab AS's financial position, as portrayed in its financial statements, is often influenced by management's estimates, judgments, and sometimes even manipulations. In the best case, Genmab AS's management is honest, while the outside auditors are strict and uncompromising. Please utilize our Beneish M Score to check the likelihood of Genmab AS's management manipulating its earnings.